The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis

Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial

(2020) W. Joseph Herring et al.   Alzheimers & Dementia

Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder

(2020) Yves Dauvilliers et al.   ANNALS OF NEUROLOGY

Lemborexant: First Approval

(2020) Lesley J. Scott   DRUGS

Sleep and Pain in Subjects with Fibromyalgia and Comorbid Insomnia: Double-blind, Crossover, Study of Suvorexant 20 mg versus Placebo.

(2020) Timothy Roehrs et al.   Journal of Clinical Sleep Medicine

Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis lemborexant vs suvorexant for insomnia

(2020) Taro Kishi et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder

(2020) Gary Zammit et al.   NEUROLOGY

Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2

(2020) Mikko Kärppä et al.   SLEEP

The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia

(2019) Sander Brooks et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: The SUPER‐1 study

(2019) Kazuomi Kario et al.   Journal of Clinical Hypertension

The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

(2019) Kasper Recourt et al.   Translational Psychiatry

A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity

(2018) Peter De Boer et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Insomnia in Elderly Patients: Recommendations for Pharmacological Management

(2018) Vivien C. Abad et al.   DRUGS & AGING

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder

(2017) Kathryn M Connor et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference

(2017) Jed Black et al.   SLEEP MEDICINE

Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis

(2017) Akira Kuriyama et al.   SLEEP MEDICINE REVIEWS

Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders

(2017) Fiona Auld et al.   SLEEP MEDICINE REVIEWS

Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians

(2016) Timothy J. Wilt et al.   ANNALS OF INTERNAL MEDICINE

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials

(2016) W. Joseph Herring et al.   BIOLOGICAL PSYCHIATRY

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia

(2016) Kathryn M. Connor et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study

(2016) Thomas Roth et al.   SLEEP

Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study

(2016) Thomas Roth et al.   SLEEP

Design, synthesis, and structure–activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists

(2014) Yu Yoshida et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis

(2014) Almira Chabi et al.   CEPHALALGIA

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial

(2014) David Michelson et al.   LANCET NEUROLOGY

Hypocretin (orexin) regulation of sleep-to-wake transitions

(2014) Luis de Lecea et al.   Frontiers in Pharmacology

Insomnia

(2013) Daniel J. Buysse   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial

(2012) P Hoever et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant

(2012) W. J. Herring et al.   NEUROLOGY

Prevalence and Perceived Health Associated with Insomnia Based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition Criteria: Results from the America Insomnia Survey

(2011) Thomas Roth et al.   BIOLOGICAL PSYCHIATRY

Insomnia and the Risk of Acute Myocardial Infarction

(2011) Lars E. Laugsand et al.   CIRCULATION

Nighttime Insomnia Symptoms and Perceived Health in the America Insomnia Survey (AIS)

(2011) James K. Walsh et al.   SLEEP

Insomnia and the Performance of US Workers: Results from the America Insomnia Survey

(2011) Ronald C. Kessler et al.   SLEEP

The Natural History of Insomnia

(2009) Charles M. Morin et al.   ARCHIVES OF INTERNAL MEDICINE